

Outline for December 11, 2013 Board Workshop (REVISED)

Introduction

At its December meeting, the Board will consider CIRM's recommendations regarding the Scientific Advisory Board report and the allocation of CIRM's remaining funds. The outline below sets forth the topics and the decision-points for the Board's consideration, as well as a suggested time allocation. Because some of the decisions will involve whether or not to extend funding for existing projects (i.e., Shared Labs, Training Grants, Bridges Awards, and Creativity Awards), members of the Board who are affiliated with an institution that has an award that would be affected by the decision may not participate. In order to maximize participation by Board members in the consideration of potential funding models, we will present these decisions first.

Background Information for Board Workshop

In preparation for the Board workshop on December 11th, CIRM staff has compiled background information to assist the Board in considering CIRM's recommendations regarding the Scientific Advisory Board report and the allocation of CIRM's remaining funds. These materials include the following:

- (1) A summary of current award programs and their status;
- (2) A chronological list of RFAs issued by CIRM for which the Board has not yet approved awards, along with the proposed number of awards and the cumulative dollar amount allocated by the Board in the concept plan for each RFA;
- (3) A chronological list of concept plans approved by the Board for which CIRM has not yet issued an RFA, along with the proposed number of awards and the cumulative dollar amount allocated by the Board in the concept plan;
- (4) A chronological list of scheduled future RFAs planned pursuant to the 2012 Strategic Plan, including the proposed number of awards and the proposed amount of the allocation, for concept plans that have not yet been approved by the Board; and
- (5) Information concerning the number of terminated awards and the amount involved as well as the difference by program in the amount of awards approved by the Board and the amount included in the Notice of Grant Awards after staff has conducted pre-funding administrative review.

We believe that this information will provide the context necessary for the Board to consider the recommendations regarding the Scientific Advisory Board report and the allocation of CIRM funding. However, if members of the Board believe that additional information would be helpful, we request that you contact us as soon as possible so that we can attempt to be responsive.

Outline for Presentation, Discussion, and Decision-Points for December Board Workshop

CIRM's management has made a number of recommendations in connection with the Scientific Advisory Board report that, if adopted, would have implications for CIRM's funding allocation. We have outlined the subject of these recommendations and the questions and decision-points that flow from them for the Board's consideration.

A. Presentation re SAB/Management Recommendations

1. Brief Overview Presentation regarding CIRM recommendations regarding the Scientific Advisory Board report (**Alan Trounson, 15 minutes**)

B. Presentation re Funding Allocation Under 2012 Strategic Plan

1. Presentation regarding current and future funding allocation under 2012 Strategic Plan, implication of funding decisions, and potential options to address challenges (**Pat Olson, 45 minutes**)

C. Decision-Points Regarding Specific Recommendations

1. Shared Laboratories Awards (Michael Yaffe, 10 minutes)

- a. What is current plan for Shared Lab Awards under 2012 Strategic Plan?
- b. How would continued funding of Shared Lab Awards affect 2012 Strategic Plan funding allocation?
- c. **Decision-Point/Staff Recommendation for Board's Consideration:** Discontinue funding of Shared Labs after current funding expires.

2. Training Grants (Michael Yaffe, 10 minutes)

- a. What is current plan for Training Grants under 2012 Strategic Plan?
- b. How would continued funding of Training Grants affect 2012 Strategic Plan funding allocation?
- c. **Decision-Point/Staff Recommendation for Board's Consideration:** Continue funding Training Grants by extending existing award for three years.

3. Bridges Awards (Michael Yaffe, 10 minutes)

- a. What is current plan for Bridges Awards under 2012 Strategic Plan?
- b. How would continued funding of Bridges Awards affect 2012 Strategic Plan funding allocation?

c. **Decision-Point/Staff Recommendation for Board's Consideration:** Continue funding Bridges Awards by extending existing award for three years.

4. Creativity Awards (Michael Yaffe, 10 minutes)

- a. What is current plan for Creativity Awards under 2012 Strategic Plan?
- b. How would continued funding of Creativity Awards affect 2012 Strategic Plan funding allocation?

c. **Decision-Point/Staff Recommendation for Board's Consideration:** Continue funding Creativity Awards by extending existing award for three years.

5. Selection of 6-8 Development Projects for Participation in Accelerated Development Pathway (Ellen Feigal, 1.5 hours)

- a. Should CIRM select 6-8 projects for participation in an accelerated development pathway, including committing funds necessary to take projects through Phase II?
 - i. What does an accelerated development pathway for 6-8 projects entail?
 - ii. How much money (order of magnitude) would CIRM have to allocate to fund 6-8 projects through Phase II?
 - iii. How would this commitment of funds affect the current funding allocation for future development projects under 2012 Strategic Plan, i.e., future Disease Team/Strategic Partnership rounds?

iv. **Decision-Point/Staff Recommendation for Board's Consideration:** Approve creation of Accelerated Development Pathway for 6-8 development projects.

b. **[If Board approves creation of Accelerated Development Pathway]** What would process for selecting 6-8 projects look like and what criteria would be used to prioritize projects?

- i. Discussion of competitive selection process.
- ii. Discussion of criteria for selecting projects (e.g., strength of stem cell connection).
- iii. **Decision-Point/Staff Recommendation for Board's Consideration:** Approve Concept Plan for Accelerated Development Pathway for 6-8 development projects.

6. Basic Research and Early Translational (Pat Olson, 45 minutes)

- a. What is current plan for funding basic biology/early translation awards under 2012 Strategic Plan?

b. What is the plan, if any, to continue funding successful and most promising existing ET projects as they come to a close?

c. Should CIRM consider focusing funds currently allocated for new ET V awards on: (i) moving successful and most promising existing ET projects toward IND; (ii) funding new Tools & Tech or Immunology RFA; (iii) funding ET Transition awards?

d. How much money would CIRM need to fund successful and most promising existing projects to IND?

e. **Decision-Point/Staff Recommendation for Board's Consideration:** Allocate ET V funds for (i) moving successful and most promising existing ET projects toward IND; (ii) funding new Tools & Tech or Immunology RFA; (iii) funding ET Transition awards.

7. Haplotype Bank (Alan Trounson, 45 minutes)

a. CIRM has the opportunity to participate in a global effort to create a GMP-quality haplotype bank.

i. How would committing funds to a haplotype program affect CIRM's future funding allocation?

ii. **Decision-Point/Staff Recommendation for Board's Consideration:** Commit \$10 million for CIRM's participation in global haplotype bank.

D. Presentation re Gollub Report

1. Presentation regarding CIRM Strategic Roadmap report (**Alan Trounson, 1 hour**).